{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-051603","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.527784+00:00","generated_at":"2026-05-16T21:24:10.566840+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lyell reports Q3 net loss $38.8M, cash $320M; acquires LYL273 CAR T for mCRC with 67% ORR","bullets":["Net loss $38.8M vs $44.6M YoY; non-GAAP net loss $29.1M.","Cash $320M, expected to fund pipeline into 2027.","Acquired exclusive global rights to LYL273 (GCC-targeted CAR T) from ICT; Phase 1 data: 67% ORR at highest dose in refractory mCRC.","FDA granted RMAT designation for ronde-cel in 2L LBCL; PiNACLE-H2H Phase 3 trial expected to start by early 2026.","Two ronde-cel abstracts accepted for oral presentation at ASH 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-051603","json":"https://secwatch.observer/filing/0001628280-25-051603.json","markdown":"https://secwatch.observer/filing/0001628280-25-051603.md","text":"https://secwatch.observer/filing/0001628280-25-051603.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000162828025051603/0001628280-25-051603-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000162828025051603/lyel-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:24:10.566840+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}